NCT06145373 - A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

September 19, 2026

Study Completion Date

November 30, 2029

Conditions

Hemophilia A

Interventions

DRUG

Fitusiran (SAR439774)

Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous (SC) injection

BIOLOGICAL

Clotting factor concentrates (CFC) or bypassing agents (BPA)

Pharmaceutical form: Solution for injection-Route of administration: Intravenous (IV) injection

BIOLOGICAL

Antithrombin concentrate (ATIIIC)

Pharmaceutical form:Solution for injection-Route of administration:Intravenous (IV) injection

BIOLOGICAL

Emicizumab

Pharmaceutical form:Solution for injection-Route of administration:SC injection

Trial Locations (2)

RECRUITING

Investigational Site Number : 1580001, Taipei

RECRUITING

Children's Hospital Los Angeles- Site Number : 8400005, Los Angeles